Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. April 2021 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON to Report First Quarter 2021 Financial Results and Company Highlights on May 5, 2021

SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
23. März 2021 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Poster Presentation at the 2021 AACR Virtual Annual Meeting

SAN DIEGO, March 23, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
09. März 2021 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
08. März 2021 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
02. März 2021 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
25. Februar 2021 16:03 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
18. Februar 2021 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON to Report Fourth Quarter and Full Year 2020 Financial Results and Company Highlights on February 25, 2021

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
19. Januar 2021 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
06. Januar 2021 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
30. Dezember 2020 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...

Vorherige Seite

Nächste Seite